Avian Influenza. Bird Flu. H5N1.
It’s a virus that boasts a mortality rate above 60%. In China, it kills two out of three infected.
And for the first time ever, the highly-virulent H5N1 has crossed into the Americas.
One week ago, the first human infection of H5N1 was reported in Canada. But it won’t be the last.
I don’t want to scare you, because we’re not at pandemic levels—yet. H5N1 still can’t easily spread from person-to-person. And until that happens, we’re mostly safe here in the U.S.
But in the meantime, this virus is endemic in China. Tens of millions of birds have been slaughtered and disposed of to limit the spread of bird flu, but human cases there continue to surge because of the virus’ fast-mutation ability.
In fact, two out of three people infected in China die within days. Just take the latest report from the woman returning from a vacation in Beijing.
- She felt unwell on her return flight to Alberta on December 27.
- She was hospitalized on New Year’s Day.
- And she died on January 3, only seven days from her first symptoms.
More troubling, she had no exposure to poultry while she was there.
And there is just one company that has the technology and the know-how, not to mention the full support of the Chinese government to fight this potential epidemic.
Buy Shares Today, and Enjoy Double-Digit Gains In Six Months…
…And Triple-Digit Profits in a Year!
Already, this stock is up 10% since the latest H5N1 case in Canada was released, and this is just the beginning of an explosive move higher for these shares.
This company—I’ll call it our #1 Biotech Winner of 2014— is one of the most innovative Chinese small-cap stocks that I’ve ever found.
It dominates its niche because it is consistently able to adapt and create vaccines for the latest infectious disease trends far faster than its giant pharmaceutical competitors.
And in the case of H5N1, speed is a necessity.
That’s because these flu viruses are fast mutating, with one already developing a resistance to Roche’s Tamiflu and GlaxoSmithKline’s Relenza according to the Chinese Center for Disease Control and Prevention in Beijing.
And that’s why the Chinese government chose this company’s vaccine over the lumbering pharma giants as the only licensed H5N1 vaccine for China’s strategic stockpile.
But Wall Street is entirely overlooking this company—I guarantee that you won’t have heard of this stock.
In fact, there is just a single analyst following the company, and if you’ll forgive me for a moment, he’s had a history of being dead wrong.
- Last quarter, this analyst expected the company to report a loss. Instead, the company reported a modest gain—surprising some 300% to the upside. And handing us hefty gains in the process.
- The quarter before that, wrong again. To the tune of a 133% earnings surprise.
- Before that, a 60% earnings surprise.
So rather than getting better, this poor overworked analyst is actually getting worse!
The next opportunity for a massive earnings surprise is coming up…
…because this analyst is STILL expecting the company to report a loss in the next quarter. And I have to say, I think we’re on the verge of an even bigger earnings upset.
That’s because the company is no one-hit wonder. It stands to benefit—and massively so—as H5N1 continues to rear its deadly head, or if we see another outbreak of H1N1, but it also has a number of other profitable vaccines for diseases like hepatitis A, hepatitis B, influenza and SARS.
And its latest vaccine is set to fight the Chinese epidemic of EV71, or Hand Foot and Mouth Disease, as cases continue to accelerate—from just over one million in 2010 to more than two million in 2012. There is no other treatment for EV71, and the company just completed its phase III clinical trials with strong results.
What about its pipeline? Vaccines for pneumococcal, rotavirus, rabies, varicella, and rubella.
And the best part is that this vaccine powerhouse is still small enough to double…or triple…in the next year. In fact, it has all the same promise as our previous triple-digit biotech winners Santarus (SNTS) for locked-in 612% gains and Valeant Pharma (VRX) for its 209% off-the-table profits.
Of course, in the worse-case scenario…if we were to see a repeat of the 1918 Spanish Flu, the deadliest epidemic in modern history…this company would be in a prime position to save some of the millions of lives that would be lost.
I’ve put together the full story for you on these this opportunity in my latest special report titled “Three Biotechs for Triple-Digit Gains in 2014” that I just uploaded to my Emerging Growth website.
Full details on how to reserve your copy, free of charge—as well as how to buy shares in this company now, before it surges again—in just a moment.
But first, I want to discuss two more biotech stocks with robust portfolios and even stronger pipelines in addition to this powerful vaccine maker…
Two Blockbuster Biotechs for Big 2014 Gains
Our #2 Biotech Winner of 2014 is a royalty powerhouse with one of the largest and most diversified portfolios in the industry.
Last year was its “break-out” year—two approvals, 6 Phase III results filed, two orphan designations and a whopping 20 net assets added to its portfolio.
And 2014 is going to be even better—with revenue generating drugs expected to double over the next year.
Not to mention that this company has a whopping $700 million in milestone payments from existing deals…Plus, another $800 million in projected R&D investment by its partners over the next year…With more than 80 clinical trials to be run in 2014…And royalties for its current assets are projected to exceed $2.2 billion over the next three years.
That’s a whole lot of big numbers for an overlooked stock that still trades at just a $1.3 billion market cap.
This may be our next 600%+ winner, just like Santarus last year, particularly since it keeps taking shots on goal.
Its latest drug is a novel new diabetes treatment with blockbuster potential. Before that, curing hot flashes. Before that, a treatment that cleans the toxic “plaque” that causes Alzheimer’s disease.
And those are just its latest launches.
So with the company’s revenue doubling and its stunning earnings numbers, I expect it will keep racking up the regulatory approvals and handing us smooth and steady gains through the year ahead.
Finally, our #3 Biotech Winner of 2014 has a unique claim to fame—it’s immune from scrutiny by the Food and Drug Administration.
This company solves the manufacturing challenges as drug-making shifts—from traditional pharmaceutical synthesis via everyday chemicals to bio-compounds that are purified from living organisms like bacteria.
I’m especially excited about its “Factory of the Future” rollout as biomanufacturing moves from permanent glass-and-steel production facilities to ones that can use disposable products that drastically reduce the time needed for purification, ups efficiency and lowers cost.
We’re already enjoying 100%+ gains in this stock, and there’s plenty more upside to go as the company continues to blow out earnings and raise its forward guidance.
And I want to make sure that you’re on board with us to profit. That’s why I’ve put all the details behind these three stocks in Three Biotechs for Triple-Digit Gains in 2014.
This report is immediately yours to keep, with the full names and opportunity behind these three stunning biotechs that are set to double…or even triple…all within the next year.
Note: If you are already a member of Emerging Growth, you can check out the next biotech doublers right now in this special report on the subscribers-only website). If you’re not currently a member of Emerging Growth, keep reading!
I Can’t Tell You Their Names Here
You won’t find these companies being talked about around the water cooler this year, but next year, you’ll be able to boast that you found them first.
Before the Wall Street pros. Before the hedge funds and the mutual funds. And before the final wave of retail investors.
In fact, right now the only place that you’ll find the full names and details on these three triple-digit biotechs is on our private website, exclusively for members in good standing.
And given these companies’ proven ability to jump 10%… 20%… even 40% in a matter of days on just a slight increase in investor interest, the time to get on board is now—NOT later.
Why The Time To Buy Is Now
Last year was a stunning year for Emerging Growth, one of our Top 5 Best on record since I started sharing my stock-picking system with individual investors.
And that’s saying something, because we’ve beaten the market by a whopping $9 to $1 over the last 10 years—1,337% gains vs. the market’s 152% increase.
In fact, if you had invested just $5,000 in our current list of stunning buys, you would be currently sitting on $97,173 in profits.
If you decided that index investing was “safer” and instead stuck $5,000 into the S&P 500 each time we made a buy, you would have just $22,137.
That’s a $75,000 difference, and my readers couldn’t be happier:
So what do I expect for 2014?
I’m confident that our performance in the last year is just the beginning of one of the most significant wealth-building opportunities of the past 30 years.
And I want to offer you a deal that you can’t afford to ignore—to the tune of $75,000 a year.
I don’t want you to get left behind this year…like you were in 2013…and to help make this a “no-brainer” decision, I guarantee that you’ll profit, or you’ll pay nothing.
Take a 90-Day Test Drive
That’s right; you have a full 90 days to try my Emerging Growth service…
…90 days to buy our stocks
…90 days to receive my buy and sell alerts
…90 days to see our small-cap stocks begin to pay off and head for triple-digit gains in 2014.
Then make your decision whether Emerging Growth is for you.
To make this the easiest decision possible, I’ve asked my publisher to lower the price of Emerging Growth this weekend only.
A regular year’s subscription to my small-cap service costs $1,295. But today, we’re opening up our membership roster for just $295.
Join today, buy as many of my recommended stocks as possible, and see for yourself. Last year, an annual membership would have paid for itself 75 times over.
And in 2014, our small-caps are poised to surge on incredible tailwinds…This is one of the most significant wealth-building opportunities of the past 30 years as the market finally gets “smart” and chases fewer and fewer stocks.
I’ll be there with you every step of the way—trade-by-trade, week-by-week and month-after-month in order to reduce risk, find the most innovative small-cap stocks and keep your portfolio balanced and growing.
But the catch is that you MUST join today, before this special price passes you by and these positions move higher without you. Accept this offer today and enjoy the $75,000 difference in 2014.
Editor, Emerging Growth
P.S. These three biotech stocks will simply not wait around. If you plan to profit in 2014, you need to be in these three positions with triple-digit upside. Read the full story in my latest special report titled “Three Biotechs for Triple-Digit Gains in 2014” that I just uploaded to my Emerging Growth website.